Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301: On Track to File for FDA Approval Mid-2025
Results Have Been Submitted Ahead of In-Person Meeting with FDA Set for April 2CTx-1301 is the First, True, Once-Daily Stimulant Medication to ...
Pharmabiz19d
US FDA approves Mirum’s Ctexli tablets to treat cerebrotendinous xanthomatosis
Mirum Pharmaceuticals, Inc. announced that the US Food and Drug Administration (FDA) has approved Ctexli (chenodiol) tablets, a bile acid, for the treatment of adults with cerebrotendinous ...